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BACKGROUND
A fluoropyrimidine plus irinotecan or oxaliplatin, combined with bevacizumab 
(a monoclonal antibody against vascular endothelial growth factor), is standard 
first-line treatment for metastatic colorectal cancer. Before the introduction of 
bevacizumab, chemotherapy with fluorouracil, leucovorin, oxaliplatin, and irinote-
can (FOLFOXIRI) showed superior efficacy as compared with fluorouracil, leucovo-
rin, and irinotecan (FOLFIRI). In a phase 2 study, FOLFOXIRI plus bevacizumab 
showed promising activity and an acceptable rate of adverse effects.
METHODS
We randomly assigned 508 patients with untreated metastatic colorectal cancer to 
receive either FOLFIRI plus bevacizumab (control group) or FOLFOXIRI plus beva-
cizumab (experimental group). Up to 12 cycles of treatment were administered, 
followed by fluorouracil plus bevacizumab until disease progression. The primary 
end point was progression-free survival.
RESULTS
The median progression-free survival was 12.1 months in the experimental group, 
as compared with 9.7 months in the control group (hazard ratio for progression, 
0.75; 95% confidence interval [CI], 0.62 to 0.90; P = 0.003). The objective response 
rate was 65% in the experimental group and 53% in the control group (P = 0.006). 
Overall survival was longer, but not significantly so, in the experimental group 
(31.0 vs. 25.8 months; hazard ratio for death, 0.79; 95% CI, 0.63 to 1.00; P = 0.054). 
The incidences of grade 3 or 4 neurotoxicity, stomatitis, diarrhea, and neutropenia 
were significantly higher in the experimental group.
CONCLUSIONS
FOLFOXIRI plus bevacizumab, as compared with FOLFIRI plus bevacizumab, im-
proved the outcome in patients with metastatic colorectal cancer and increased the 
incidence of some adverse events. (Funded by the Gruppo Oncologico Nord Ovest 
and others; ClinicalTrials.gov number, NCT00719797.)
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Primary treatment with two-drug combinations of fluorouracil (plus leuco-vorin) and either irinotecan (FOLFIRI) or 
oxaliplatin (FOLFOX) plus bevacizumab are wide-
ly adopted treatments for metastatic colorectal 
cancer.1,2 Initial treatment strategies led to simi-
lar results regardless of which drug — irinote-
can or oxaliplatin — was used3; therefore, the 
choice of the primary treatment regimen is com-
monly based on the physician’s or patient’s pref-
erences, regional differences, and whether the 
patient has or has not already received an adju-
vant oxaliplatin-containing treatment.4
In the pivotal phase 3, randomized study 
AVF2107g,1 the addition of bevacizumab to irino-
tecan and bolus fluorouracil (plus leucovorin) 
led to an improvement in objective response rate, 
progression-free survival, and overall survival. 
Bevacizumab was added to irinotecan and infu-
sional fluorouracil in a phase 4 trial, producing 
similar results.5
A triple-drug combination of f luorouracil 
(plus leucovorin), oxaliplatin, and irinotecan 
(FOLFOXIRI) proved to be feasible and highly 
active in phase 2 studies.6,7 In a phase 3 study 
conducted by the Gruppo Oncologico Nord Ovest 
(GONO), 12 cycles of treatment with FOLFOXIRI 
showed a superior response rate, progression-
free survival, and overall survival as compared 
with 12 cycles of FOLFIRI.8
The efficacy and safety of FOLFOXIRI plus 
bevacizumab were previously tested in a phase 2 
study,9 and a response rate of 77% was reported; 
median progression-free survival was 13.1 months, 
and median overall survival was 30.9 months. The 
rate of adverse events was consistent with the rate 
shown in the phase 3 study conducted by GONO8 
and was higher than the rate associated with 
FOLFOX or FOLFIRI. On the basis of such prom-
ising results, we conducted the present random-
ized study of FOLFOXIRI plus bevacizumab as 
compared with FOLFIRI plus bevacizumab in pa-
tients with previously untreated metastatic colorec-
tal cancer.
Me thods
Study Design and Oversight
The Triplet plus Bevacizumab (TRIBE) study was 
a phase 3, randomized, open-label, multicenter 
trial conducted in 34 Italian centers and involving 
patients with unresectable metastatic colorectal 
cancer who had not received chemotherapy or 
biologic therapy for their metastatic disease but 
may have received adjuvant chemotherapy earlier 
in the disease course. The study was conducted 
in accordance with the Declaration of Helsinki 
and adhered to Good Clinical Practice guidelines. 
Approval for the protocol was obtained from the 
local ethics committee for each participating site. 
All patients provided written informed consent, 
including a separate, specific signature consenting 
to blood sampling and specimen donation for 
translational analyses.
Patients were assigned in a 1:1 ratio to receive 
up to 12 cycles of FOLFOXIRI plus bevacizumab 
(experimental group) or FOLFIRI plus bevaciz-
umab (control group). Maintenance treatment 
with fluorouracil plus bevacizumab until tumor 
progression was then administered in both 
groups. Stratification criteria were Eastern Co-
operative Oncology Group (ECOG) performance 
status (a score of 0 vs. 1 or 2 on a scale of 0 to 5, 
with 0 indicating no symptoms and higher scores 
indicating increasing symptoms), center, and pre-
vious adjuvant treatment (yes vs. no).
The primary end point was progression-free 
survival, defined as the time from randomiza-
tion to disease progression according to Response 
Evaluation Criteria in Solid Tumors (RECIST), ver-
sion 1.0,10 or death from any cause. Tumor as-
sessment was centrally reviewed. Secondary end 
points included response rate, overall survival rate, 
resection rate of metastases, and rate of adverse 
events. Adverse events were graded according to 
the National Cancer Institute Common Termi-
nology Criteria for Adverse Events (CTCAE), ver-
sion 3.0.11
The study was designed by the three senior 
academic investigators and sponsored by GONO. 
Bevacizumab for the treatment of patients en-
rolled in the experimental group was supplied by 
F. Hoffmann–La Roche, which had no other role 
in the study. Data were collected by the sponsor 
and were analyzed by the statistician. The three 
senior academic investigators had access to all 
the data and vouch for the completeness and ac-
curacy of the reported data and adherence to the 
protocol, which is available with the full text of 
this article at NEJM.org. The preliminary draft 
of the manuscript was written by the first and 
second authors with the assistance of the cor-
responding author. All the authors revised sub-
sequent drafts and made the decision to submit 
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the manuscript for publication. No one who is 
not an author contributed to the manuscript.
Patients
Main inclusion criteria were an age between 18 
and 75 years, ECOG performance status score of 
2 or less (patients above 70 years of age were 
eligible if their ECOG performance status score 
was 0), histologically confirmed adenocarcinoma 
of the colon or rectum, a first occurrence of 
metastatic disease that was deemed unresectable 
with curative intent, measurable disease accord-
ing to RECIST version 1.0, and adequate func-
tioning of the bone marrow, liver, and kidneys. 
Main exclusion criteria were adjuvant treatment 
with oxaliplatin completed less than 12 months 
before relapse, peripheral neuropathy of grade 1 
or higher according to CTCAE version 3.0, evi-
dence of bleeding diathesis or coagulopathy, un-
controlled hypertension, clinically significant car-
diovascular events within 6 months before study 
entry, serious cardiac events requiring medication, 
New York Heart Association class II or higher 
heart failure, and the need for full-dose antico-
agulation.
Treatment
Patients in the control group received up to 12 
cycles of FOLFIRI plus bevacizumab, consisting 
of a 30-minute infusion of bevacizumab at a dose 
of 5 mg per kilogram of body weight, a 60-minute 
infusion of irinotecan at a dose of 180 mg per 
square meter of body-surface area, a 120-minute 
infusion of leucovorin at a dose of 200 mg per 
square meter, and a bolus of fluorouracil at a dose 
of 400 mg per square meter followed by a 46-hour 
continuous infusion of fluorouracil to a total dose 
of 2400 mg per square meter. Cycles were re-
peated every 14 days. Patients in the experimental 
group received up to 12 cycles of FOLFOXIRI plus 
bevacizumab, consisting of a 30-minute infusion 
of bevacizumab at a dose of 5 mg per kilogram, 
a 60-minute infusion of irinotecan at a dose of 
165 mg per square meter, and a 120-minute in-
fusion of oxaliplatin at a dose of 85 mg per square 
meter and a concomitant 120-minute infusion of 
leucovorin at a dose of 200 mg per square meter, 
followed by a 48-hour continuous infusion of 
fluorouracil to a total dose of 3200 mg per square 
meter. Cycles were repeated every 14 days.
Thereafter, in both groups, maintenance treat-
ment with bevacizumab, fluorouracil, and leuco-
vorin was continued until disease progression, 
the occurrence of an unacceptable adverse event, 
or withdrawal of consent. In cases of prespecified 
adverse events, treatment modifications were per-
mitted according to study protocol.
Assessments
Tumor assessment by means of computed to-
mography was performed every 8 weeks until 
the evidence of disease progression. At the start 
of every cycle, the patients’ medical history, ECOG 
performance status, results of physical examina-
tion, and adverse events were recorded.
To assess KRAS and BRAF mutational status, 
DNA was extracted from archival tissue specimens 
from the primary tumor or metastasis. KRAS 
codons 12, 13, and 61 and BRAF codon 600 were 
centrally analyzed by means of pyrosequencing, 
as previously reported.11
Statistical Analysis
The trial was planned as a phase 3, randomized 
study. We planned to enroll 450 patients in order 
to observe 379 events of disease progression or 
death from any cause; with that number of events, 
it was estimated that the study would have 80% 
power to detect a hazard ratio for progression of 
0.75 at a two-sided significance level of 5%. All 
efficacy analyses were performed on an intention-
to-treat basis. The median period of follow-up 
was calculated for the entire study cohort accord-
ing to the reverse Kaplan–Meier method. Distri-
butions of time-to-event variables were estimated 
with the use of the Kaplan–Meier product-limit 
method. The stratified log-rank test was used as 
the primary analysis for comparison of treatment 
groups. Cox proportional-hazards modeling was 
also performed as supportive analyses. Subgroup 
analyses of progression-free survival were per-
formed by means of an interaction test to deter-
mine the consistency of the treatment effect ac-
cording to key baseline characteristics. Overall 
survival was analyzed with the same methods as 
those used for the analysis of progression-free 
survival. The objective response rate, the resec-
tion rate for metastases, and the incidence of ad-
verse events in the two groups were compared 
with the use of the chi-square test for heteroge-
neity or with Fisher’s exact test when appropriate. 
All statistical tests were two-sided, and P values 
of 0.05 or less were considered to indicate statis-
tical significance. Odds ratios and 95% confidence 
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intervals were estimated with a logistic-regression 
model, and hazard ratios and 95% confidence 
intervals were estimated with a Cox proportional-
hazards model. No adjustment for multiple com-
parisons was made.
R esult s
Study Population
From July 2008 through May 2011, a total of 508 
patients from 34 Italian centers were enrolled in 
the study; 256 patients were randomly assigned 
to FOLFIRI plus bevacizumab (control group) and 
252 to FOLFOXIRI plus bevacizumab (experimental 
group) and were included in the intention-to-
treat population. Two patients in each group did 
not receive any cycle of treatment according to 
their random assignment and therefore were not 
included in the safety population, which com-
prised patients who had received at least one 
cycle of the assigned treatment (Fig. 1). The 
cutoff date for the collection of follow-up data 
was April 26, 2013.
Demographic and baseline characteristics of 
the patients were similar in the two groups 
(Table 1), but a higher percentage of patients in 
the experimental group than in the control 
group had a primary tumor in the right colon 
Figure 1. Randomization and Treatment.
FOLFIRI denotes fluorouracil, leucovorin, and irinotecan; and FOLFOXIRI fluorouracil, leucovorin, oxaliplatin, and 
irinotecan.
508 Patients underwent randomization
256 Were included in the intention-to-treat
population and were assigned to receive 
FOLFIRI plus bevacizumab
252 Were included in the intention-to-treat
population and were assigned to receive
FOLFOXIRI plus bevacizumab
2 Were not treated 2 Were not treated
254 Were included in safety population 250 Were included in safety population
115 Were excluded
77 Discontinued before
completing the 12th
cycle
54 Had disease 
progression
4 Died
9 Had adverse event
10 Had other reasons
38 Underwent surgery
108 Were excluded
62 Discontinued before
completing the 12th
cycle
34 Had disease 
progression
6 Died
21 Had adverse event
1 Had other reason
46 Underwent surgery
139 Were candidates for maintenance phase 142 Were candidates for maintenance phase
25 Were withdrawn from
maintenance phase
by investigator
12 Were withdrawn from
maintenance phase
by investigator
114 Were included in the maintenance phase
and received fluorouracil plus bevacizumab
130 Were included in the maintenance phase
and received fluorouracil plus bevacizumab
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(34.9% vs. 23.8%, P = 0.02). Altogether, 89.8% of 
the study population had a score of 0 on the 
ECOG performance status scale, 79.5% present-
ed with synchronous metastases, 32.7% had an 
unresected primary tumor, and 12.6% had previ-
ously received an adjuvant treatment. Of all the 
enrolled patients, 79.3% had multiple sites of 
metastases, and 20.7% had disease limited to 
the liver. KRAS was analyzed in 407 patients 
(80.1%), and BRAF in 406 patients (79.9%); 39.4% 
had KRAS mutations, and 5.5% had BRAF muta-
tions.
The median number of cycles administered 
per patient as induction treatment was 12 (range, 
1 to 25) in the control group and 11 (range, 1 to 
21) in the experimental group. According to the 
investigator’s choice, 23 patients in the control 
group and 12 patients in the experimental group 
received more than the 12 planned cycles, result-
ing in a protocol violation. More cycles were 
delayed in the experimental group than in the 
control group (16.4% vs. 6.1%, P<0.001), and 
more cycles were administered with a reduced 
dose (21.4% vs. 8.2%, P<0.001). Dose reductions 
were not permitted for bevacizumab. In the con-
trol group, the average relative dose intensities 
of fluorouracil and irinotecan were 83% and 
84%, respectively. In the experimental group, 
the average relative dose intensities of fluoroura-
cil, irinotecan, and oxaliplatin were 73%, 74%, 
and 75%, respectively. More patients in the con-
trol group than in the experimental group dis-
continued treatment because of disease progres-
sion (20.1% vs. 12.8%, P = 0.03).
A total of 139 patients in the control group 
and 142 patients in the experimental group were 
candidates for maintenance therapy after the 
induction phase (Fig. 1); 114 patients in the con-
trol group (82.0%) and 130 patients in the ex-
perimental group (91.5%) actually received 
maintenance therapy.
Efficacy
The median duration of follow-up was 32.2 
months (range, 24.7 to 40.6). The progression-
free survival analysis was based on 439 events 
among the 508 patients (86.4%). More events 
occurred in the 256 patients in the control group 
than in the 252 patients in the experimental 
group (226 [88.3%] vs. 213 [84.5%]). The medi-
an progression-free survival times were 12.1 
Characteristic
FOLFIRI 
plus 
Bevacizumab 
(N = 256)
FOLFOXIRI 
plus 
Bevacizumab 
(N = 252)
Age — yr
Median 60.0 60.5
Range 29–75 29–75
Sex — no. (%)
Male 156 (60.9) 150 (59.5)
Female 100 (39.1) 102 (40.5)
ECOG performance status — no. (%)
0 229 (89.5) 227 (90.1)
1–2 27 (10.5) 25 (9.9)
Site of primary tumor — no. (%)
Right colon 61 (23.8) 88 (34.9)†
Left colon or rectum 179 (70.0) 152 (60.3)
Missing data 16 (6.2) 12 (4.8)
Previous adjuvant therapy — no. (%) 32 (12.5) 32 (12.7)
Time to metastases — no. (%)
Synchronous 207 (80.9) 197 (78.2)
Metachronous 49 (19.1) 55 (21.8)
Metastases — no. (%)
Confined to liver 46 (18.0) 59 (23.4)
At multiple sites 210 (82.0) 193 (76.6)
Unresected primary tumor — no. (%) 89 (34.8) 77 (30.6)
Köhne prognostic score — no. (%)
High-risk 29 (11.3) 18 (7.1)
Intermediate-risk 113 (44.2) 111 (44.0)
Low-risk 105 (41.0) 108 (42.9)
Missing data 9 (3.5) 15 (6.0)
KRAS — no. (%)
Nonmutated 99 (38.7) 94 (37.3)
Mutated 96 (37.5) 104 (41.3)
Not definable 6 (2.3) 8 (3.2)
Missing data 55 (21.5) 46 (18.2)
BRAF — no. (%)
Nonmutated 183 (71.5) 182 (72.2)
Mutated 12 (4.7) 16 (6.3)
Not definable 6 (2.3) 7 (2.8)
Missing data 55 (21.5) 47 (18.7)
*  ECOG denotes Eastern Cooperative Oncology Group; FOLFIRI fluorouracil, 
leucovorin, and irinotecan; and FOLFOXIRI fluorouracil, leucovorin, oxaliplat-
in, and irinotecan.
†  A significantly higher percentage of patients in the group assigned to 
FOLFOXIRI plus bevacizumab than in the group assigned to FOLFIRI plus 
bevacizumab had a primary tumor in the right colon (P = 0.02).
Table 1. Baseline Characteristics of the Patients in the Intention-to-Treat 
Population.*
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months for FOLFOXIRI plus bevacizumab and 
9.7 months for FOLFIRI plus bevacizumab. 
FOLFOXIRI plus bevacizumab was associated 
with a 25% reduced risk of progression as com-
pared with FOLFIRI plus bevacizumab (hazard 
ratio for progression, 0.75; 95% confidence in-
terval [CI], 0.62 to 0.90; P = 0.003) (Fig. 2A). An 
ECOG performance status score of 1 or 2, a 
primary tumor in the right colon, synchronous 
metastases, disease not confined to the liver, an 
unresected primary tumor, a high score on the 
Köhne index12 (a model in which the prognosis 
of patients with metastatic colorectal cancer is 
classified as low-risk, intermediate-risk, or high-
Figure 2. Kaplan–Meier Estimates of Progression-free and Overall Survival, According to Treatment Group.
Median progression-free survival was 9.7 months in the group receiving FOLFIRI plus bevacizumab (control group) 
and 12.1 months in the group receiving FOLFOXIRI plus bevacizumab (experimental group). Median overall survival 
was 25.8 months in the control group and 31.0 months in the experimental group.
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risk according to ECOG performance status, 
number of metastatic sites, white-cell count, and 
alkaline phosphatase level; see the Supplemen-
tary Appendix, available at NEJM.org), and a 
BRAF mutation were identified as adverse prog-
nostic factors for progression-free and overall 
survival in the univariate model (see the Supple-
mentary Appendix). At an exploratory analysis 
adjusting for these variables, the hazard ratio for 
progression associated with FOLFOXIRI plus 
bevacizumab was 0.75 (95% CI, 0.62 to 0.92; 
P = 0.006). BRAF mutational status was not in-
cluded in the adjusted model because data were 
missing for 20.1% of the patients. The benefit of 
FOLFOXIRI plus bevacizumab with respect to 
progression-free survival was homogeneous in 
clinical and molecular subgroups, except for 
patients who had previously received adjuvant 
treatment. A significant interaction between 
exposure to a previous adjuvant treatment and 
progression-free survival was observed (P = 0.04) 
(Fig. 3).
The response rate was 53.1% in the control 
group, as compared with 65.1% in the experi-
mental group (odds ratio, 1.64; 95% CI, 1.15 to 
2.35; P = 0.006) (Table 2). The rate of R0 resec-
tion of metastases (i.e., no macroscopic or mi-
croscopic residual tumor) was not significantly 
different in treatment groups (12% in the con-
trol group vs. 15% in the experimental group, 
P = 0.33).
The overall survival analysis was based on 
286 deaths among the 508 patients (56.3%). 
More deaths occurred in the control group than 
in the experimental group (155 [60.5%] vs. 131 
[52.0%]). The median overall survival times were 
Figure 3. Forest Plot of the Treatment Effect on Progression-free Survival in Subgroup Analyses.
The size of the squares is proportional to the size of the corresponding subgroup. Control denotes FOLFIRI plus 
bevacizumab, ECOG Eastern Cooperative Oncology Group, and experimental FOLFOXIRI plus bevacizumab.
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31.0 months in the experimental group and 25.8 
months in the control group, which corresponds 
to a hazard ratio for death of 0.79 (95% CI, 0.63 
to 1.00; P = 0.054); this decrease did not meet the 
criterion for statistical significance. At the ex-
ploratory analysis adjusting for prognostic vari-
ables, the hazard ratio for death with FOLFOXIRI 
plus bevacizumab was 0.72 (95% CI, 0.56 to 0.94; 
P = 0.01) (Fig. 2B).
Safety
Treatment-related grade 3 or 4 adverse events 
occurring in at least 3% of patients are summa-
rized in Table 3. The incidence of grade 3 or 4 
neutropenia, diarrhea, stomatitis, and neurotox-
icity (i.e., peripheral neuropathy) was signifi-
cantly higher in the experimental group than in 
the control group. No significant differences in 
bevacizumab-related adverse events were ob-
served between groups. The incidence of serious 
adverse events was similar in the two groups 
(19.7% in the control group and 20.4% in the 
experimental group, P = 0.91).
A total of 142 (91.6%) of the deaths in the 
control group and 121 (92.4%) of the deaths in 
the experimental group were attributed to dis-
ease progression. In each group, a similar num-
ber of patients died as a result of adverse events 
(4 [1.6%] in the control group and 6 [2.4%] in 
the experimental group).
Subsequent Treatments
Second-line treatment was administered in 173 
patients in the control group and in 166 patients 
in the experimental group (see Table S5 in the 
Supplementary Appendix). Among patients re-
ceiving a second-line treatment, a higher per-
centage of patients in the control group than in 
the experimental group received an oxaliplatin-
containing regimen (64% vs. 23%). In the con-
trol group, another 14% of patients received ox-
aliplatin as part of the third-line or fourth-line 
treatment. In the control group, 31% of patients 
continued bevacizumab beyond disease progres-
sion, as did 30% in the experimental group, and 
29% of patients in the control group and 33% in 
the experimental group received an anti–epider-
mal growth factor receptor monoclonal antibody 
as second- or third-line treatment.
Discussion
This phase 3, randomized study showed im-
proved progression-free survival among patients 
Variable
FOLFIRI 
plus Bevacizumab 
(N = 256)
FOLFOXIRI 
plus Bevacizumab 
(N = 252)
Hazard Ratio 
or Odds Ratio 
(95% CI)† P Value
Progression-free survival
Progression event — no. of patients (%) 226 (88.3) 213 (84.5) 0.75 (0.62–0.90) 0.003
Months of progression-free survival — median (95% CI) 9.7 (9.3–10.9) 12.1 (10.9–13.2)
Response — no. (%)
Complete response 8 (3.1) 12 (4.8)
Partial response 128 (50.0) 152 (60.3)
Stable disease 82 (32.0) 62 (24.6)
Progressive disease 27 (10.6) 16 (6.3)
Not evaluated 11 (4.3) 10 (4.0)
Overall response rate
No. (%) 136 (53.1) 164 (65.1) 1.64 (1.15–2.35) 0.006
95% CI 46.8–59.3 58.8–70.9
Overall survival
Deaths — no. (%) 155 (60.5) 131 (52.0) 0.79 (0.63–1.00) 0.054
Months of overall survival — median (95% CI) 25.8 (22.7–30.8) 31.0 (26.9–35.1)
*  CI denotes confidence interval.
†  The ratios listed are hazard ratios, except for the overall response rate, for which the odds ratio is shown.
Table 2. Efficacy in the Intention-to-Treat Population, According to Treatment Group.*
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with metastatic colorectal cancer after treatment 
with the combination of FOLFOXIRI plus beva ci z-
 umab as compared with FOLFIRI plus bevaciz-
umab (hazard ratio for progression, 0.75; 95% 
CI, 0.62 to 0.90; P = 0.003). The median progres-
sion-free survival was prolonged by 2.4 months, 
reaching 12.1 months in the experimental group. 
Moreover, an absolute increase of 12.0% in re-
sponse rate was reported, and median overall 
survival was extended, but not significantly so, 
by 5.2 months, from 25.8 to 31.0.
In line with the findings in previous trials,8,9 
treatment with FOLFOXIRI or FOLFOXIRI plus 
bevacizumab was feasible in a multicenter col-
laboration. The intensification of the treatment 
was associated with a significant increase in the 
rates of grade 3 or 4 neurotoxicity, stomatitis, 
diarrhea, and neutropenia. However, no signifi-
cant differences between treatment groups in 
the rates of febrile neutropenia, serious adverse 
events, or deaths due to treatment-related toxic 
effects were observed. In our opinion, early rec-
ognition and active management of adverse 
events is crucial. The percentage of bevacizu-
mab-related adverse events was consistent with 
the percentages in previous trials, and no signifi-
cant differences between groups were reported, 
thus showing that chemotherapy intensification 
does not influence the safety profile of the anti-
angiogenic agent. A limitation is that we did not 
assess patients’ health-related quality of life.
To exploit the potential benefit of a more in-
tensive treatment without compromising its fea-
sibility, specific selection criteria were adopted. 
Patients older than 75 years of age were exclud-
ed, and for those between 70 and 75 years of 
age, an ECOG performance status of 0 was re-
quired. Subgroup analyses did not reveal any 
interaction between baseline characteristics and 
treatment effect, with the exception of previous 
exposure to adjuvant chemotherapy. Indeed, pa-
tients who previously received adjuvant treat-
ment, which contained oxaliplatin in 64% of 
cases, derived no benefit from treatment inten-
sification. Therefore, patients who have received 
adjuvant chemotherapy are not ideal candidates 
for an intensified up-front chemotherapy.
No significant interaction between the extent 
of the metastatic disease (confined to the liver 
vs. not confined to the liver) and treatment ef-
fect was apparent. In the present trial, most pa-
tients had diffuse, extrahepatic disease. We did 
not focus on the challenge of converting patients 
with liver metastases into candidates for surgi-
cal resection and cannot assess the role of inten-
sified therapy toward that goal.
From a clinical perspective, the up-front con-
comitant use of the three cytotoxic agents raises 
questions about possible options for subsequent 
salvage therapy. Unfortunately, data on the out-
come of second and subsequent therapies were 
not collected systematically in this study. How-
ever, 78% of patients who were randomly as-
signed to receive the experimental treatment 
received components of the primary regimen as 
part of their second-line treatment after they had 
disease progression. The overall survival benefit 
with the four-drug regimen might not have been 
observed if the efficacy of these salvage treat-
ments had been compromised. A maintenance 
phase and a continuum of care for patients with 
metastatic colorectal cancer are supported by 
recent results and recommended by major guide-
lines.4,13-15
Another question is whether chemotherapy 
plus bevacizumab should be the preferred option 
for patients with nonmutated RAS tumors. Pre-
liminary data on triplet chemotherapy plus ce-
tuximab or panitumumab were promising, and 
randomized studies are ongoing. A recent phase 3, 
randomized trial16 comparing FOLFIRI plus ce-
tuximab with FOLFIRI plus bevacizumab showed 
Event
FOLFIRI 
plus 
Bevacizumab 
(N = 254)
FOLFOXIRI 
plus 
Bevacizumab 
(N = 250) P Value
no. (%)
Neutropenia 52 (20.5) 125 (50.0) <0.001
Febrile neutropenia 16 (6.3) 22 (8.8) 0.32
Diarrhea 27 (10.6) 47 (18.8) 0.01
Stomatitis 11 (4.3) 22 (8.8) 0.048
Nausea 8 (3.2) 7 (2.8) 1.00
Vomiting 8 (3.2) 11 (4.4) 0.49
Asthenia 23 (9.1) 30 (12.0) 0.31
Peripheral neuropathy 0 13 (5.2) <0.001
Hypertension 6 (2.4) 13 (5.2) 0.11
Venous thromboembolism 15 (5.9) 18 (7.2) 0.59
Serious adverse events 50 (19.7) 51 (20.4) 0.91
*  Events listed are those that occurred in at least the 3% of patients in either 
treatment group.
Table 3. Most Common Grade 3 or 4 Adverse Events.*
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no significant difference between treatment 
groups in the response rate, the primary end 
point, or progression-free survival in the non-
mutated RAS subgroup. However, treatment with 
FOLFIRI plus cetuximab was associated with an 
improvement in overall survival as compared with 
FOLFIRI plus bevacizumab. In our trial, the treat-
ment effect was independent of KRAS status.
In conclusion, our findings show that 6 months 
of induction treatment with FOLFOXIRI plus 
bevacizumab (as compared with FOLFIRI plus 
bevacizumab), followed by maintenance therapy, 
significantly improved the efficacy of first-line 
therapy. The cost was an increase in the inci-
dence of adverse events.
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